<DOC>
	<DOCNO>NCT01122355</DOCNO>
	<brief_summary>The purpose study compare efficacy tolerability fenofibrate 160 mg niacin 1500 mg patient hypertriglyceridemia low HDL-cholesterol . The primary end point percent change apoB/A1 secondary end point lipid parameter biomarkers .</brief_summary>
	<brief_title>Comparison Fenofibrate Niacin Patients With Hypertriglyceridemia Low High-Density Lipoprotein ( HDL ) -Cholesterol</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<criteria>Triglyceride 150500 mg/dL HDLcholesterol &lt; 45 mg/dL 8 week dietary run period 2079 year old Lowdensity lipoprotein ( LDL ) cholesterol â‰¥ 130 mg/dL without lipidmodifying drug History cerebrovascular cardiovascular disease Creatinine &gt; 2.0 mg/dL Transaminase &gt; 2x upper limit normal Gall bladder disease Cancer Pregnant breast feeding woman History adverse event associate test drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>